Current Opinion in Lipidology volume 28, issue 6, P470-476 2017 DOI: 10.1097/mol.0000000000000453 View full text
|
|
Share
Anthony S. Wierzbicki

Abstract: The efficacy and expense of novel treatments is challenging traditional guideline development. Previously guideline committees used only to review clinical efficacy and safety endpoints but now they also have to consider costs to derive recommendations that are practical to implement.